Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Matica Biotech Names Dr. Yun Jeong Song as CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Matica Biotech Names Dr. Yun Jeong Song as CEO

Song's background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Matica Biotechnology Inc.’s board of directors has appointed Yun Jeong Song, MD, as the company’s new chief executive officer to continue its expansion as a CDMO supporting the global cell and gene therapy industry.
 
Experience
 
Song joined the company effective April 1, 2021 after 3 years as CEO of ImmuneOncia Therapeutics, an international joint venture developing immuno-oncology therapies. She succeeds Byung Se So, PhD, who will remain with Matica Bio as an advisor.
 
Song’s background spans more than 20 years of basic research, patient care and biopharmaceutical industry leadership. Prior to ImmuneOncia Therapeutics, she held positions at the U.S. National Institutes of Health, Samsung, and Sanofi.
 
“I am very excited to lead Matica Bio, a scientifically sophisticated and ambitious company,” commented Song. “My goal is to further establish the company as a respected, reliable partner to our clients, and advance our continued global expansion in this very active and dynamic field of viral vector manufacturing. We are here to fully support our clients, providing the technology and know-how to help them deliver innovative drugs to patients worldwide.”
 
So remarked, “We are delighted to have Dr. Song join the company as CEO. Her demonstrated ability to drive the growth of an innovative drug development pipeline, advancing novel therapies to the clinic, will be extremely valuable in helping Matica Bio execute on our promise to clients who are delivering advanced therapies and vaccines to address unmet needs.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters